Fig. 3

miRNA-27a and 134. a Serum miRNA-27a and 134 levels during the time course of acute pulmonary embolism (APE, 1st day: presentation at the emergency department, 3rd and 5th day during the hospital stay (n = 30) and 9 ± 1.5 months thereafter (n = 22). Values represent relative levels with the pulmonary embolism (PE) “9 months” group set as 1 (mean ± SEM, *p < 0.05, **p < 0.01). b Serum miRNA-27a and 134 levels from acute PE patients (APE, 1st day, n = 30) in comparison to patients with acute non ST-segment elevation myocardial infarction (NSTEMI, n = 30), acute deep vein thrombosis without concomitant PE (DVT, n = 6), chronic non-thromboembolic pulmonary hypertension (PH, n = 15) and healthy individuals (n = 12). Values represent relative levels with the “healthy” group set as 1 (mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001). c ROC (Receiver operating characteristic) curve analysis for miRNA-27a and 134 to discriminate acute PE (1st day) from acute NSTEMI (red line, area under the curve (AUC) 0.78, 0.78, p < 0.001, < 0.001, respectively), acute DVT (blue line, AUC 0.83, 0.84, p < 0.05, < 0.01, respectively), chronic PH (orange line, AUC 0.66, 0.67, p = 0.09, 0.06, respectively) and healthy individuals (green line, AUC 0.79, 0.84, p < 0.01, < 0.001, respectively)